U.S., Dec. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07303842) titled 'Effect of a Low Advanced Glycation End Products Diet of Patients With Type 2 Diabetes Mellitus' on Dec. 11.
Brief Summary: The present study showed that a reduction of approximately 56% in CML consumption promoted a 30% reduction in this blood biomarker. This effect was associated with increased fiber intake and reduced consumption of polyunsaturated fatty acids, trans fatty acids, and cholesterol, in addition to a positive linear correlation with lipid peroxidation, body water, and dPFGAs. This represents a potential benefit, given that these factors favor insulin resistance (IR) and vascular endothelial injury, and consequently, t...